Clinicopathologic features of SMARCB1/INI1-deficient pancreatic undifferentiated rhabdoid carcinoma: A case report and review of literature

Table 1 Previously reported undifferentiated pancreatic carcinomas with rhabdoid features (n = 55)

Ref.	Histology	Age (years)/sex	Site	Size (cm)	Treatment	Metastasis	Prognosis
Guillan[34], 1968	Pleomorphic ADCA	65/M	Head	10	Palliative	Yes	DOD 3 months
	Pleomorphic ADCA	59/M	Body/tail	6	Palliative	Yes	DOD 3 months
	Pleomorphic ADCA	72/M	Body/tail	8	Palliative	Yes	DOD 4 months
	Pleomorphic ADCA	75/M	Body/tail	9	Palliative	Yes	DOD 5 months
	Pleomorphic ADCA	62/M	Body/tail	15	Palliative	Yes	DOD 3 months
Alguacil-Garcia and Weiland[33], 1977	Round cell anaplastic carcinoma	78/M	Body	30	Biopsy	Lung, liver	DOD in few days
	Round cell anaplastic carcinoma	74/M	Tail	15	Surgery + chemotherapy	None	DOD 4 months
	Round cell anaplastic carcinoma	51/F	Head	5	Surgery	Lymph node	DOD 1 months
	Round cell anaplastic carcinoma	73/M	Diffuse	11	Biopsy	Lymph node, adrenals	DOD in few days
	Round cell anaplastic carcinoma	30/M	Body	12	Autopsy	Lymph node, ileum, kidney, thyroid, lung	NS
Tschang et al[39], 1977	Pleomorphic carcinoma	67/M	Tail	3	Biopsy	Lymph node, liver, extra-abdominal	DOD median 3 months, mean 6 months
	Pleomorphic carcinoma	49/M	Tail	NS	Biopsy	Lymph node, extra-abdominal	DOD median 3 months, mean 6 months
	Pleomorphic carcinoma	54/M	Body/tail	NS	Biopsy	Lymph node, liver, extra-abdominal	DOD median 3 months, mean 6 months
	Pleomorphic carcinoma	65/M	Tail	NS	Autopsy	Lymph node, liver, extra-abdominal	DOD median 3 months, mean 6 months
	Pleomorphic carcinoma	72/M	Body	NS	Autopsy	Lymph node, liver, extra-abdominal	DOD median 3 months, mean 6 months
	Pleomorphic carcinoma	61/M	Body	NS	Biopsy	Lymph node, liver, peritoneum	DOD median 3 months, mean 6 months
	Pleomorphic carcinoma	72/M	Head/body	10	Biopsy	Lymph node, liver, extra-abdominal	DOD median 3 months, mean 6 months
	Pleomorphic carcinoma	65/M	Body/tail	NS	Biopsy + chemotherapy	Lymph node, liver, extra-abdominal	DOD median 3 months, mean 6 months
	Pleomorphic carcinoma	69/M	Head	10	Biopsy + chemotherapy	Liver, peritoneum	DOD median 3 months, mean 6 months
	Pleomorphic carcinoma	65/M	Body/tail	NS	Biopsy + chemotherapy	Lymph node, liver, extra-abdominal	DOD median 3 months, mean 6 months
	Pleomorphic carcinoma	72/M	Head	10	Biopsy	Lymph node, liver, extra-abdominal	DOD median 3 months, mean 6 months
	Pleomorphic carcinoma	53/M	Diffuse	10	Biopsy	Lymph node, liver, extra-abdominal	DOD median 3 months, mean 6 months
	Pleomorphic carcinoma	81/F	Body/tail	15	Biopsy	Lymph node, liver, extra-abdominal	DOD median 3 months, mean 6 months
	Pleomorphic carcinoma	79/F	Head	10	Biopsy	Lymph node	DOD median 3 months, mean 6 months
Reyes et al[45], 1980	Pleomorphic giant cell carcinoma	59/M	Head	Mean 9	Supportive	Lymph node, widespread	DOD 1 month
	Pleomorphic giant cell carcinoma	37/M	Tail	Mean 9	Chemotherapy	Lymph node, widespread	DOD 13 months
	Pleomorphic giant cell carcinoma	59/M	Head	Mean 9	Supportive	Lymph node, widespread	DOD 1 month
	Pleomorphic giant cell carcinoma	71/M	Head	Mean 9	Palliative surgery	Lymph node, widespread	DOD 2 months
	Pleomorphic giant cell carcinoma	70/M	Head	Mean 9	Supportive	Lymph node, widespread	DOD 3 months
	Pleomorphic giant cell carcinoma	77/M	Head	Mean 9	Supportive	Lymph node, widespread	DOD 1 month
	Pleomorphic giant cell carcinoma	64/M	Head	Mean 9	Supportive	Lymph node, widespread	DOD 2 months
	Pleomorphic giant cell carcinoma	62/M	Head	Mean 9	Palliative surgery	Lymph node, widespread	DOD 1 month
	Pleomorphic giant cell carcinoma	54/M	Body	Mean 9	Supportive	Lymph node, widespread	DOD 4 months
Nishihara et al[35], 1997	Carcinoma with rhabdoid features	52/F	NS	10	Surgery	Lymph node, liver	DOD 19 months
Al-Nafussi and O'Donnell[46], 1999	Adeno carcinoma extensive rhabdoid	77/F	NS	NS	No	Soft tissue, liver, lung, kidney, heart, adrenals	DOD initially
Kuroda et al[38], 2007	Anaplastic carcinoma with rhabdoid features	68/F	NS	14	Palliative	Regional, bronchial	DOD 2 months
	Anaplastic carcinoma with rhabdoid features	59/M	NS	10	Surgery + chemotherapy	Liver	DOD 2 months
Chadha et al[47], 2004	Anaplastic pancreatic carcinoma	74/F	Tail	NS	Palliative	Lymph node, liver, adrenal, peritoneum	DOD 2 weeks
Cho et al[37], 2006	Carcinoma mucinous rhabdoid features	65/F	Tail	11	Surgery + RT	Omentum, mesentery, liver, lung	DOD 12 months
Jamali et al[36], 2007	ADSCA rhabdoid	75/M	NS	3	Surgery	Liver	DOD 6 months
Layfield and Bentz[40], 2008	Pleomorphic giant cell carcinoma	71/M	Head	NS	Surgery	Liver	Alive 2 months
	Pleomorphic giant cell carcinoma	81/F	Head	NS	Palliative	NS	DOD 3 months
	Pleomorphic giant cell carcinoma	59/M	Head	NS	Surgery	Lymph node, liver	Alive 3 months
	Pleomorphic giant cell carcinoma	81/M	Head	NS	Palliative	NS	NS
	Pleomorphic giant cell carcinoma	64/M	Body	NS	Palliative	Lymph node	Alive 4 months
	Anaplastic carcinoma	63/M	NS	10	Supportive	Synchronous, liver	DOD 11 days
Agaimy et al[8], 2015	Rhabdoid	76/M	Head	5	Surgery	NS	DOD 1 month
	Rhabdoid, angiosarcoma-like	44/F	Head	6	Surgery	NS	NS
	Rhabdoid, pseudopapillary acantholytic gland-like spaces	72/M	Head	4	Surgery	Liver, lymph node nodes	DOD postoperatively
	Rhabdoid, prominent neutrophils and focal glandular formation	61/M	Tail	5	Surgery	Intra-abdominal, stomach	NS
Sano et al[41], 2014	Rhabdoid	68/F	Body/tail	10	Palliative	Liver, kidneys, lungs, right adrenal gland, omentum, peritoneum	DOD in 2 weeks
Ohike et al[42], 2007	Rhabdoid, solid/diffuse	35/F	Head	6	Chemotherapy	Liver	DOD in 7 months
Tahara et al[43], 2018	Rhabdoid, solid/diffuse	67/F	Body	1.9	Chemotherapy	Liver, lung, bone, tongue, right thigh	DOD in 6 months
King et al[44], 2021	Rhabdoid; monomorphic epithelioid	59/F	Tail	1.6	Neoadjuvant FOLFIRINOX; distal pancreatectomy; adjuvant gemcitabine/paclitaxel	Liver	Disease-free 20 months
Our case	Rhabdoid	59/F	Tail	4.5	Gemcitabine/nab-paclitaxel; bevacizumab/toripalimab	Spleen, kidney, retroperitoneum	Alive 6 months

ADCA: Adreno carcinoma; ADSCA: Adenosquamous carcinoma; NS: Not specific; M: Male; F: Female; RT: Tadiation therapy; DOD: Day of dead.